Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Matthew Seymour, MD: A Clinical Trialist’s Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




May
24
Today In Oncology
Guideline-Concordant Care Is Associated With Improved Survival. So, Why Aren’t More AYA Patients Receiving This Care?
Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States
Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status
FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer
Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo